News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  26th August 2013  
  Oncogenic Roles of PRL-3 in FLT3-ITD Induced Acute Myeloid Leukemia
 
 




Authors
Jung Eun Park1, Hiu Fung Yuen1, Jian Biao Zhou2, Abdul Qader O. Al-aidaroos1, Ke Guo1, Peter J Valk3, Shu Dong Zhang4, Wee Joo Chng2,5,6, Cheng William Hong7, Ken Mills4 and Zeng Qi1,8, *

1  - Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research),       Singapore
2  - Cancer Science Institute of Singapore, National University of Singapore, Singapore
3  - Department of Hematology, Erasmus University Medical Center Rotterdam, Netherlands
4  - Centre for Cancer Research and Cell Biology, Queen's University Belfast, United Kingdom
5  - Department of Haematology-Oncology, National University Cancer Institute, Singapore
6  - Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore,       Singapore
7  - Cleveland Clinic Lerner College of Medicine, USA.
8  - Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore,       Singapore

* Corresponding author: Zeng Qi: mcbzengq@imcb.a-star.edu.sg

Published in EMBO Molecular Medicine on 8 August 2013.

Abstract

FLT3-ITDmutations are prevalent mutations in acute myeloid leukemia (AML). PRL-3, a metastasis-associated phosphatase, is a downstream target of FLT3-ITD. This study investigates the regulation and function of PRL-3 in leukemia cell lines and AML patients associated with FLT3-ITD mutations. PRL-3 overexpression is mediated by the FLT3-STAT5 signalling pathway in leukemia cells, leading to an activation of AP-1 transcription factors via ERK and JNK pathways. PRL-3-depleted AML cells showed a significant decrease in cell growth. Clinically, high PRL-3 mRNA expression was associated with FLT3-ITD mutations in 4 independent AML datasets with 1158 patients. Multivariable Cox-regression analysis on our Cohort 1 with 221 patients identified PRL-3 as a novel prognostic marker independent of other clinical parameters. Kaplan-Meier analysis showed high PRL-3 mRNA expression was significantly associated with poorer survival among 491 patients with normal karyotype. Targeting PRL-3 reversed the oncogenic effects in FLT3-ITD AML models in vitro and in vivo. Herein, we suggest that PRL-3 could serve as a prognostic marker to predict poorer survival and as a promising novel therapeutic target for AML patients.

Figure Legend: PRL-3 mRNA levels are elevated inFLT3-ITD-positive AML samples
A. RT-PCR analysis of PRL-3 mRNA expression levels in 19 bone marrow samples from AML patients either negative (ITD NEG; n = 12) or positive (ITD POS; n = 7) for FLT3-ITD mutation. MOLM-14 and MV4-11 AML cell lines were used as FLT3-ITD positive controls. β-actin, loading control.

B.
(a-d) Microarray data analysis of PRL-3 mRNA levels in FLT-ITD-positive (POS) or FLT3-ITD-negative (NEG) patients in four independent patient cohorts (total n = 1158). a. Cohort 1 AML patient with normal karyotype (n = 101, p = 0.001). b. GSE1159 AML patient cohort (n = 285, p < 0.001). c. GSE6891 AML patient cohort (n = 521, p < 0.001). d. GSE15434 AML patient cohort (n = 251, p < 0.001). Statistical differences between ITD-POS and ITD-NEG patients were determined using Chi-square test. PRL-3 expression level is divided into 4 groups; Very high, High, Intermediate, Low

C
. Western blot analysis of PRL-3 protein levels in four AML cell lines.

D
. Western blot analysis of PRL-3 in MOLM-14 and MV4-11 cells upon siRNA-mediated knock-down of FLT3 expression. NS, control non-silencing siRNA. GAPDH, loading control.

For more information on Qi ZENG’s laboratory, please click here.